| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.94▼ | 3.99▼ | 4.01▼ | 4.30▼ | 4.48▼ |
| MA10 | 4.07▼ | 4.13▼ | 4.15▼ | 4.65▼ | 2.89▲ |
| MA20 | 4.20▼ | 4.29▼ | 4.38▼ | 4.70▼ | 1.71▲ |
| MA50 | 4.51▼ | 4.71▼ | 4.75▼ | 2.70▲ | 1.42▲ |
| MA100 | 4.77▼ | 4.78▼ | 4.89▼ | 1.64▲ | 2.20▲ |
| MA200 | 4.84▼ | 3.35▲ | 2.64▲ | 1.38▲ | 6.99▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.029▼ | -0.026▼ | -0.048▼ | -0.261▼ | 0.411▲ |
| RSI | 21.809▼ | 22.774▼ | 26.020▼ | 46.398▼ | 67.044▲ |
| STOCH | 0.000▼ | 1.220▼ | 0.538▼ | 19.086▼ | 66.740 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -100.000▼ | -44.364 |
| CCI | -137.145▼ | -172.829▼ | -166.429▼ | -197.516▼ | 50.335 |
|
Thursday, July 30, 2026 01:03 AM
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally ...
|
|
Wednesday, July 22, 2026 05:25 AM
Curis, Inc. (NASDAQ:CRIS) shares climbed 11% on Wednesday after the biotechnology company released encouraging updated clinical data for emavusertib in patients with Primary CNS Lymphoma (PCNSL) and ...
|
|
Friday, June 26, 2026 06:42 AM
LEXINGTON, Mass., June 26, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 10/08/26 | 3.98 | 3.98 | 3.83 | 3.83 | 28,972 |
| 07/08/26 | 4.35 | 4.35 | 3.955 | 4.02 | 69,370 |
| 06/08/26 | 4.49 | 4.6999 | 4.02 | 4.41 | 78,923 |
| 05/08/26 | 4.84 | 4.87 | 4.39 | 4.545 | 54,497 |
| 04/08/26 | 5.14 | 5.2799 | 4.6129 | 4.72 | 85,443 |
| 03/08/26 | 5.13 | 5.495 | 5.07 | 5.15 | 83,992 |
| 31/07/26 | 5.00 | 5.1727 | 4.918 | 5.02 | 14,178 |
| 30/07/26 | 5.02 | 5.54 | 4.85 | 4.96 | 62,344 |
| 29/07/26 | 4.90 | 5.06 | 4.90 | 4.98 | 66,593 |
| 28/07/26 | 4.69 | 4.88 | 4.65 | 4.83 | 26,754 |
|
|
||||
|
|
||||
|
|